[Drug treatment of proliferative vitreoretinopathy].
The steps in the formal pathogenesis of proliferative vitreoretinopathy (inflammation, proliferation, the synthesis of extracellular matrix, and contraction) provide the target points for medical treatment. A survey of the relevant drugs is given. Anti-inflammatory agents (steroids, heparin) and antiproliferative agents (colchicine, daunomycin, and fluoropyrimidines) are discussed, as are anticollagen agents (penicillamin and cis-hydroxyprolin). Clinical studies were performed with colchicine, daunomycin, fluorouracil, and steroids. Our experimental and clinical data indicate that the therapeutical results might be improved by the combination of two drugs. A two-factorial, controlled clinical study is proposed, using an antiproliferative and an anti-inflammatory drug.
Wiedemann
P
P
D001813:Blood-Retinal Barrier / Q000187:drug effects*; D003078:Colchicine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D006909:Hydroxyproline / Q000008:administration & dosage; D007536:Isomerism; D010396:Penicillamine / Q000008:administration & dosage; D012162:Retinal Degeneration / Q000188:drug therapy*; D013256:Steroids / Q000008:administration & dosage; D014822:Vitreous Body / Q000187:drug effects*
D013256:Steroids; C026215:3-hydroxyproline; D006493:Heparin; D010396:Penicillamine; D006909:Hydroxyproline; D003078:Colchicine; D005472:Fluorouracil; D003630:Daunorubicin
Die medikamentöse Behandlung der proliferativen Vitreoretinopathie.